185 related articles for article (PubMed ID: 37558736)
1. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Othman J; Potter N; Mokretar K; Taussig D; Khan A; Krishnamurthy P; Latif AL; Cahalin P; Aries J; Amer M; Belsham E; Conneally E; Craddock C; Culligan D; Dennis M; Duncan C; Freeman SD; Furness C; Gilkes A; Gkreka P; Hodgson K; Ingram W; Jain M; King A; Knapper S; Kottaridis P; McMullin MF; Mohite U; Ngu L; O'Nions J; Patrick K; Rider T; Roberts W; Severinsen MT; Storrar N; Taylor T; Russell NH; Dillon R
Leukemia; 2023 Oct; 37(10):2066-2072. PubMed ID: 37558736
[TBL] [Abstract][Full Text] [Related]
2. Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD.
Takahashi K; Kantarjian H; Pemmaraju N; Andreeff M; Borthakur G; Faderl S; Garcia-Manero G; Pierce S; Luthra R; Cardenas-Turanzas M; Estrov Z; Ravandi F; Cortes J
Br J Haematol; 2013 Jun; 161(5):659-666. PubMed ID: 23530930
[TBL] [Abstract][Full Text] [Related]
3. Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.
Yilmaz M; Alfayez M; DiNardo CD; Borthakur G; Kadia TM; Konopleva MY; Loghavi S; Kanagal-Shamanna R; Patel KP; Jabbour EJ; Garcia-Manero G; Pemmaraju N; Pierce SA; Ghayas I; Short NJ; Montalban-Bravo G; Takahashi K; Assi R; Alotaibi AS; Ohanian M; Andreeff M; Cortes JE; Kantarjian HM; Ravandi F; Daver NG
J Hematol Oncol; 2020 Oct; 13(1):132. PubMed ID: 33032648
[TBL] [Abstract][Full Text] [Related]
4. Which FLT3 Inhibitor for Treatment of AML?
Senapati J; Kadia TM
Curr Treat Options Oncol; 2022 Mar; 23(3):359-380. PubMed ID: 35258791
[TBL] [Abstract][Full Text] [Related]
5. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
[TBL] [Abstract][Full Text] [Related]
6. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib as a Salvage Therapy in FLT3-ITD Negative Relapse/ Refractory Acute Myeloid Leukemia.
Yang N; Gu Z; Liu Z; Huang W; Wang S; Wang L; Gao C
Anticancer Agents Med Chem; 2018; 18(10):1489-1494. PubMed ID: 29521250
[TBL] [Abstract][Full Text] [Related]
8. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
[TBL] [Abstract][Full Text] [Related]
9. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
Antar AI; Otrock ZK; Jabbour E; Mohty M; Bazarbachi A
Leukemia; 2020 Mar; 34(3):682-696. PubMed ID: 31919472
[TBL] [Abstract][Full Text] [Related]
10. Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation.
Helbig G; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kopińska A; Boral K; Grygoruk-Wiśniowska I; Stachowicz M; Karolczyk A
Ann Hematol; 2020 Aug; 99(8):1845-1853. PubMed ID: 32333156
[TBL] [Abstract][Full Text] [Related]
11. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
[TBL] [Abstract][Full Text] [Related]
12. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
[TBL] [Abstract][Full Text] [Related]
13. Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.
Liang EC; Chen C; Lu R; Mannis GN; Muffly L
Bone Marrow Transplant; 2021 Dec; 56(12):3091-3093. PubMed ID: 34584238
[TBL] [Abstract][Full Text] [Related]
14. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of FLT3 in AML: a focus on sorafenib.
Antar A; Otrock ZK; El-Cheikh J; Kharfan-Dabaja MA; Battipaglia G; Mahfouz R; Mohty M; Bazarbachi A
Bone Marrow Transplant; 2017 Mar; 52(3):344-351. PubMed ID: 27775694
[TBL] [Abstract][Full Text] [Related]
17. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.
Al Hamed R; Labopin M; Daguindau E; Niittyvuopio R; Huynh A; Socié G; Srour M; Henri Bourhis J; Kröger N; Tholouli E; Choi G; Poiré X; Martin H; Rubio MT; Jindra P; Blaise D; Beelen D; Labussière-Wallet H; Nagler A; Bazarbachi A; Mohty M
Cancer Med; 2022 Feb; 11(4):1068-1080. PubMed ID: 35048553
[TBL] [Abstract][Full Text] [Related]
19. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With
Burchert A; Bug G; Fritz LV; Finke J; Stelljes M; Röllig C; Wollmer E; Wäsch R; Bornhäuser M; Berg T; Lang F; Ehninger G; Serve H; Zeiser R; Wagner EM; Kröger N; Wolschke C; Schleuning M; Götze KS; Schmid C; Crysandt M; Eßeling E; Wolf D; Wang Y; Böhm A; Thiede C; Haferlach T; Michel C; Bethge W; Wündisch T; Brandts C; Harnisch S; Wittenberg M; Hoeffkes HG; Rospleszcz S; Burchardt A; Neubauer A; Brugger M; Strauch K; Schade-Brittinger C; Metzelder SK
J Clin Oncol; 2020 Sep; 38(26):2993-3002. PubMed ID: 32673171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
